Trials / Conditions / Pathologic Stage IIID Cutaneous Melanoma AJCC v8

Pathologic Stage IIID Cutaneous Melanoma AJCC v8

20 registered clinical trials studyying Pathologic Stage IIID Cutaneous Melanoma AJCC v8 — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients NCT05176470	Richard Wu	Phase 1
Recruiting	Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positiv NCT05098210	Fred Hutchinson Cancer Center	Phase 1
Recruiting	Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors NCT07259304	University of Southern California	—
Active Not Recruiting	A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment i NCT04708418	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or NCT04940299	M.D. Anderson Cancer Center	Phase 2
Terminated	Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement NCT04221438	ECOG-ACRIN Cancer Research Group	Phase 2
Recruiting	IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801	M.D. Anderson Cancer Center	Phase 1
Terminated	Bone Loss in Melanoma Survivors Receiving Immunotherapy NCT04516122	M.D. Anderson Cancer Center	—
Terminated	Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Recruiting	Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer NCT03819296	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV NCT04462406	ECOG-ACRIN Cancer Research Group	Phase 2
Terminated	Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype NCT04375527	Jonsson Comprehensive Cancer Center	Phase 2
Terminated	Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage III NCT04310397	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immuno NCT04990726	M.D. Anderson Cancer Center	—
Active Not Recruiting	Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or M NCT03816332	National Cancer Institute (NCI)	Phase 1
Terminated	Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma NCT03865212	Mayo Clinic	Phase 1
Active Not Recruiting	VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma NCT03769155	Emory University	Phase 1
Active Not Recruiting	Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma NCT03554083	Mayo Clinic	Phase 2
Active Not Recruiting	Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986	Roswell Park Cancer Institute	Phase 1 / Phase 2
Terminated	Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495	M.D. Anderson Cancer Center	Phase 1